nidufexor   Click here for help

GtoPdb Ligand ID: 10655

Synonyms: compound 1 [PMID: 31940200] | LMB-763 | LMB763
Compound class: Synthetic organic
Comment: Nidufexor (LMB763) is an orally bioavailable non-bile acid agonist of the ligand-activated nuclear farnesoid X receptor (FXR) that is being developed by Novartis for the treatment of nonalcoholic steatohepatitis (NASH) [1]. FXR agonists reduce steatosis, hepatocellular inflammation, hepatic injury and fibrosis.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 84.66
Molecular weight 487.13
XLogP 5.35
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES Clc1ccc2c(c1)c1n(C)nc(c1CO2)C(=O)N(Cc1ccc(cc1)C(=O)O)Cc1ccccc1
Isomeric SMILES Clc1ccc2c(c1)c1n(C)nc(c1CO2)C(=O)N(Cc1ccc(cc1)C(=O)O)Cc1ccccc1
InChI InChI=1S/C27H22ClN3O4/c1-30-25-21-13-20(28)11-12-23(21)35-16-22(25)24(29-30)26(32)31(14-17-5-3-2-4-6-17)15-18-7-9-19(10-8-18)27(33)34/h2-13H,14-16H2,1H3,(H,33,34)
No information available.
Summary of Clinical Use Click here for help
Nidufexor (LMB763) has progressed to Phase 2 clinical evaluation in patients with diabetic nephropathy and NASH. The NASH trial is noted as 'Terminated' on, but no explanation for the termination is included.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03804879 Safety, Tolerability and Efficacy of LMB763 in Patients With Diabetic Nephropathy Phase 2 Interventional Novartis
NCT02913105 Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH Phase 2 Interventional Novartis This trial has been terminated.